Hangzhou York Biotech Secures Tens of Millions RMB in Series A Funding to Advance Product Development and Core Technology Platforms

VCBeat has learned that York Biotech (HangZhou) Co., Ltd. recently completed a Series A financing round worth tens of millions of yuan, with Triwise Capital as the investor. The funds will be used to conduct clinical trials and submit regulatory applications for a series of Class III medical device products, as well as to support the research and development of other urologic oncology pipeline products and the optimization and upgrading of core technology platforms.

Co-founded by Professor Huang Jiaoti, a world-renowned expert in pathology, and Ms. Zhu Xiaoxia, who brings extensive experience in medical project management and operations, the company is an innovative enterprise dedicated to the research, development, and manufacturing of in vitro diagnostic (IVD) reagents. Professor Huang currently serves as Chair and Tenured Professor of the Department of Pathology at Duke University. He has made profound contributions to both basic and clinical research on prostate cancer, published over 200 papers in top-tier international journals, and served as principal investigator for more than 30 projects funded by the U.S. National Institutes of Health (NIH), with total funding exceeding $66 million. Professor Huang also serves on the editorial board of the Chinese Journal of Pathology and as Associate Editor-in-Chief of the Chinese Journal of Urology, in addition to holding editorial positions for more than ten other international scientific journals. Furthermore, he acts as a peer reviewer for the U.S. National Institutes of Health and the National Natural Science Foundation of China.Since its establishment, the company has adhered to a strategic focus on “concentrating on urological tumors to achieve comprehensive diagnosis throughout the entire course of the disease.” Driven by innovation, it is committed to the R&D and commercialization of novel diagnostic products. Addressing pain points in clinical diagnostics, the company insists on independent R&D and continuous technological innovation, developing products that are first-of-their-kind domestically or internationally. It has successfully completed the R&D and clinical validation of multiple products for the early diagnosis of urological tumors. The company now operates a production base and R&D center spanning over 5,000 square meters, compliant with international GMP standards. It has been recognized as a “National High-Tech Enterprise” and designated as the “Hangzhou York Biotech Tumor Precision Diagnosis Municipal Enterprise High-Tech Research and Development Center.”

The company has currently established in-depth collaborative partnerships with West China Hospital of Sichuan University, the First Affiliated Hospital of Zhejiang University School of Medicine, the Second Affiliated Hospital of Zhejiang University School of Medicine, Nanjing Drum Tower Hospital (the Affiliated Hospital of Nanjing University Medical School), and other hospitals.

Ms. Zhu Xiaoxia, Founder of York BiotechYork Biotech (HangZhou) Co., Ltd. has remained true to its original mission since its inception, dedicating itself exclusively to the comprehensive diagnosis of urologic tumors across the entire disease course. We aim to promote standardized and widespread adoption of full-course diagnostic solutions for urologic tumors through innovative products, delivering benefits to humanity by enabling early detection and treatment, thereby reducing mortality and incidence rates of urologic cancers in China and effectively conserving national medical insurance expenditures. York Biotech is now on a fast track, experiencing rapid growth. Our products are innovative and exclusive both domestically and internationally, addressing a substantial market opportunity. We are highly confident in the future of York Biotech.

Professor Huang Jiaoti, Co-founder of York BiotechIt is evident that, in every sense, medical issues are not merely single-discipline or technical problems, but rather comprehensive challenges encompassing pathology, patient psychology, allocation of medical resources, and physicians’ professional development. York Biotech is committed to reshaping the medical ecosystem in the field of urology. After comparing the differences between Chinese and foreign diagnosis and treatment models, we have proposed an innovative “Whole-Course Tumor Diagnosis” model. We believe that our efforts will effectively integrate into the urological medical ecosystem, creating both commercial and social value while delivering high-quality services to patients and physicians.

Zheng Zhenhua, Managing Partner of Triwise CapitalStatement: We are delighted to support innovative diagnostic product developers and manufacturers like York Biotech, which are driven by clinical needs and characterized by efficient execution. With the relentless efforts and continuous innovation of its founding team and scientists, who possess profound industry experience and a global perspective, York Biotech is poised to establish a comprehensive whole-course diagnostic model for urologic tumors. We look forward to York Biotech becoming a unicorn in urology-specific diagnostics, bringing safe and efficient novel diagnostic and therapeutic solutions to more patients, thereby benefiting the broader patient population.

York Biotech (HangZhou) Co., Ltd., located in the Xiaoshan Economic and Technological Development Zone of Hangzhou, Zhejiang Province, is an innovative R&D and manufacturing enterprise specializing in in vitro diagnostic (IVD) reagents. Focusing on the niche field of urological tumor diagnosis, the company leverages two cutting-edge technological platforms—tumor liquid biopsy via exosome detection and gene editing (CRISPR/Cas). By integrating multiple leading molecular detection platforms, York Biotech conducts tracking of urological tumor diagnostic biomarkers and translational medical research based on clinical needs. It develops a series of independently innovated diagnostic products covering the entire disease course of tumors, thereby commercializing its technological achievements. York Biotech aims to become a leader in innovative diagnostic products and a unicorn enterprise in the urology specialty sector.

Shenzhen Qianhai Triwise International Capital Management Co., Ltd. (P1030072), a vice-presidential unit of the Shenzhen Venture Capital Association. Established in 2015, the company brings together financial executives from Shenzhen Capital Group and Guosen Securities, senior industry professionals from Roche, MD Anderson Cancer Center, Wantai Bio, and China Medical System Holdings, as well as scientific experts from renowned domestic and international universities. Guided by the value proposition of “redirecting investment toward the real economy and leveraging capital to serve industry,” Triwise Capital strategically layouts its industrial ecosystem, emphasizing original and value-based investing. By connecting industrial and technological platforms and engaging in “joint entrepreneurship” with industry teams, Triwise Capital empowers the commercialization of scientific research outcomes through capital strength. Triwise Capital currently maintains offices in Shenzhen, Shanghai, and Changzhou, and has initiated and established more than twenty RMB and USD-denominated funds.